Skip to content
When it comes to biotech M&A, 2024 wasn’t a great year, but it wasn’t “horrible,” according to analysts at the BIO CEO & Investor […]
M&A comeback may face political headwinds, say BIO CEO panelists Read More »
As farmers, ranchers, and biotech companies work together to keep America strong and well-fed, they need supportive policy, an expert from the Biotechnology Innovation
BIO promotes its partnership with farmers and ranchers at Farm Bureau Convention Read More »
The U.S. Food and Drug Administration’s Accelerated Approval Pathway enables the timely development of treatments for severely ill patients who have few if any
BIO coffee chat focuses on reimbursement for Accelerated Approval Pathway drugs Read More »
Seeking biotech-friendly policy from the new administration and Congress will be daunting and perhaps confusing, but there are still a lot of potential wins
BIO CEO 2025: Challenges and opportunities in the new administration Read More »
Despite a pressing demand, schizophrenia has had limited treatment. “Roughly 1% of the entire world population has schizophrenia,” said Boobalan Pachaiyappan, Managing Director and
BIO CEO 2025: New solution for the challenge of schizophrenia Read More »
The idea of AI supercharging drug development is stirring a lot of excitement. However, a realistic understanding of what AI can and can’t do
BIO CEO 2025: AI is a tool – not magic Read More »
While a couple of frontrunners have taken the early lead in the race to capture the market for obesity drugs, major pharmaceutical firms still
BIO CEO 2025: Exciting new directions for obesity drug research Read More »
Colorado’s contributions to biotechnology innovation—and biotech’s importance to our health, food supply, and national security—were key themes as BIO President & CEO John F.
John Crowley highlights Colorado’s biotech ecosystem during packed Denver tour Read More »
“This is America,” goes the musical refrain of the new Hims & Hers Super Bowl ad for its compounded obesity drugs. But Hims &
What the Hims & Hers Super Bowl commercial gets wrong about innovation… and America Read More »
With the new administration bringing new leadership to the Centers for Medicare & Medicaid Services (CMS), one of the most significant healthcare decisions facing
BIO’s message to incoming CMS leadership on improving Part D access for patients Read More »
